[go: up one dir, main page]

AR025455A1 - Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos - Google Patents

Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Info

Publication number
AR025455A1
AR025455A1 ARP000104536A ARP000104536A AR025455A1 AR 025455 A1 AR025455 A1 AR 025455A1 AR P000104536 A ARP000104536 A AR P000104536A AR P000104536 A ARP000104536 A AR P000104536A AR 025455 A1 AR025455 A1 AR 025455A1
Authority
AR
Argentina
Prior art keywords
contraception
mesoprogestines
conceptives
components
female
Prior art date
Application number
ARP000104536A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of AR025455A1 publication Critical patent/AR025455A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de mesoprogestinas para producir un producto farmacéutico para la anticoncepcion femenina, a una preparacion farmacéutica para la anticoncepcionfemenina y a un método anticonceptivo femenino que administra cantidades efectivas de unamesoprogesti na en una mujer que desea contar con anticoncepcion.Opcionalmente, la mesoprogestina puede utilizarse en combinacion con un estrogeno. Las mesoprogestinas se definen como compuestos que disponen de actividadtanto agonística comoantagonística en el r eceptor de progesterona (RP) in vivo. Estabilizan la funcion de RP en un nivel intermedio entre agonístico yantagonístico. Con las progestinas o las antiprogestinas no es posible lograr estados funcionales correspondientes.J867, J912, J956 y J1042 s on lasmesoprogestinas preferibles de acuerdo con la presente.
ARP000104536A 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos AR025455A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (1)

Publication Number Publication Date
AR025455A1 true AR025455A1 (es) 2002-11-27

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104536A AR025455A1 (es) 1999-08-31 2000-08-31 Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Country Status (28)

Country Link
EP (1) EP1605949A2 (es)
JP (1) JP2003511399A (es)
KR (1) KR20020038745A (es)
CN (1) CN1384748A (es)
AR (1) AR025455A1 (es)
AU (1) AU781835B2 (es)
BG (1) BG106441A (es)
BR (1) BR0013711A (es)
CA (1) CA2383650A1 (es)
CO (1) CO5190694A1 (es)
CZ (1) CZ2002707A3 (es)
EA (1) EA006805B1 (es)
EE (1) EE200200103A (es)
HR (1) HRP20020265A2 (es)
HU (1) HUP0202515A3 (es)
IL (1) IL148415A0 (es)
LT (1) LT5001B (es)
LV (1) LV12940B (es)
MX (1) MXPA02002186A (es)
NO (1) NO20020998L (es)
NZ (1) NZ517470A (es)
PE (1) PE20010579A1 (es)
PL (1) PL353994A1 (es)
SI (1) SI20853A (es)
SK (1) SK2982002A3 (es)
UA (1) UA77150C2 (es)
WO (1) WO2001026603A2 (es)
YU (1) YU13902A (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539016A (ja) * 2002-08-02 2005-12-22 シエーリング アクチエンゲゼルシャフト 女性用受胎調節及びホルモン置換療法のための高められた抗ゴナドトロピン活性を有するプロゲステロン受容体モジュレーター
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
JP5288796B2 (ja) * 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
US9616073B2 (en) 2009-04-14 2017-04-11 Laboratoire Hra-Pharma Method for on-demand contraception
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
DE699310C (de) 1936-11-20 1940-11-27 Chemische Ind Ges Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
FI101601B1 (fi) * 1987-09-24 1998-07-31 Jencap Research Ltd Ehkäisyvalmiste sekä estrogeenin ja progestiinin käyttö ehkäisyvalmisteen valmistusmenetelmässä
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5516769A (en) 1993-02-19 1996-05-14 The Medical College Of Hampton Roads Method of inhibiting fertilization
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4429398C2 (de) 1994-08-09 1997-09-11 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption
NZ295365A (en) * 1994-10-24 1999-07-29 Schering Ag Competitive progesterone antagonists for regulating female fertility as required
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
ATE213947T1 (de) * 1996-06-25 2002-03-15 Akzo Nobel Nv Progestogen-anti-progestogen therapien
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
CN1353717A (zh) * 1999-05-04 2002-06-12 莱加制药公司 四环黄体酮受体调节剂化合物及其方法

Also Published As

Publication number Publication date
BG106441A (bg) 2002-09-30
KR20020038745A (ko) 2002-05-23
LT5001B (lt) 2003-03-25
JP2003511399A (ja) 2003-03-25
MXPA02002186A (es) 2002-09-02
IL148415A0 (en) 2002-09-12
EP1605949A2 (en) 2005-12-21
AU781835B2 (en) 2005-06-16
SK2982002A3 (en) 2002-07-02
LT2002035A (lt) 2002-10-25
WO2001026603A3 (en) 2002-01-17
EE200200103A (et) 2003-04-15
YU13902A (sh) 2006-01-16
NO20020998L (no) 2002-03-14
EA200200284A1 (ru) 2002-10-31
EA006805B1 (ru) 2006-04-28
CZ2002707A3 (cs) 2002-11-13
PL353994A1 (en) 2003-12-15
WO2001026603A2 (en) 2001-04-19
NZ517470A (en) 2004-03-26
HRP20020265A2 (en) 2004-02-29
HUP0202515A3 (en) 2004-06-28
AU3215001A (en) 2001-04-23
UA77150C2 (en) 2006-11-15
HUP0202515A2 (hu) 2002-12-28
NO20020998D0 (no) 2002-02-28
CO5190694A1 (es) 2002-08-29
PE20010579A1 (es) 2001-06-04
SI20853A (sl) 2002-10-31
LV12940B (en) 2003-06-20
CN1384748A (zh) 2002-12-11
CA2383650A1 (en) 2001-04-19
BR0013711A (pt) 2002-05-07

Similar Documents

Publication Publication Date Title
CA2256365A1 (en) Compositions, methods and devices for the transdermal delivery of drugs
PT836506E (pt) Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
PT87053A (pt) Processo para a preparacao de composicoes contraceptivas contendo meletonina e metodo para efectuar a contracepcao
PE20051038A1 (es) Uso extendido de combinacion que comprende estrogenos y progestinas
EP1260206A3 (en) Pants-type disposable wearing article
RU2005140277A (ru) Система доставки лекарственного вещества
DK1272504T3 (da) 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener
AR035904A1 (es) 5-[2-hidroxi-3-1-(3-trifluorometilfenil)-ciclopropil-propionilamino]-ftalida y compuestos relacionados con actividad moduladora del receptor de progesterona
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
ES2162900T3 (es) Composicion liquida de l-n-mentol y procedimiento para su preparacion.
EA200900451A1 (ru) Способ получения композиции эстрадиола с медленным высвобождением ( варианты ), микросферы эстрадиола и холестерина и способ для одновременной контрацепции и гормонозамещения
AR025455A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos
EA200100108A1 (ru) Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии
WO2006053172A3 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
BR0214634A (pt) Sistemas terapêuticos transdérmicos contendo hormÈnio esteróide e contendo monocaprilato de propilenoglicol
EP1890758B1 (en) Dosage form cap for an applicator
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
AR033160A1 (es) Producto absorbente
PE20060318A1 (es) Forma de administracion para la contracepcion hormonal
AR025457A1 (es) Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
AR025456A1 (es) Mesoprogestinas (moduladores de receptor de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (trh)
DE10250470A1 (de) Körperhygieneartikel aus saugfähigem Material - Urin-Rest-Absorber (URA) für Männer
KR970005295A (ko) 죽염과 운모를 유효성분으로 함유하는 질정제
ATE546144T1 (de) Verwendung von estradiolvalerat in kombination mit dienogest zur oralen therapie der dysf unktionellen uterinen blutung in einheit mit einer oralen kontrazeption
Hurst Dunedin research on IUDs

Legal Events

Date Code Title Description
FB Suspension of granting procedure